- Home
- OPTN vs ITRM Comparison
OPTN vs ITRM Comparison
Compare OPTN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- ITRM
- Stock Information
- Founded
- OPTN 2010
- ITRM 2015
- Country
- OPTN United States
- ITRM Ireland
- Employees
- OPTN N/A
- ITRM N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- ITRM Health Care
- Exchange
- OPTN Nasdaq
- ITRM Nasdaq
- Market Cap
- OPTN 55.4M
- ITRM 49.5M
- IPO Year
- OPTN 2017
- ITRM 2018
- Fundamental
- Price
- OPTN $5.77
- ITRM $1.49
- Analyst Decision
- OPTN Strong Buy
- ITRM Strong Buy
- Analyst Count
- OPTN 3
- ITRM 1
- Target Price
- OPTN $16.67
- ITRM $5.00
- AVG Volume (30 Days)
- OPTN 18.9K
- ITRM 635.0K
- Earning Date
- OPTN 03-06-2025
- ITRM 02-07-2025
- Dividend Yield
- OPTN N/A
- ITRM N/A
- EPS Growth
- OPTN N/A
- ITRM N/A
- EPS
- OPTN N/A
- ITRM N/A
- Revenue
- OPTN $75,672,000.00
- ITRM N/A
- Revenue This Year
- OPTN $13.42
- ITRM N/A
- Revenue Next Year
- OPTN $38.54
- ITRM $160.88
- P/E Ratio
- OPTN N/A
- ITRM N/A
- Revenue Growth
- OPTN 5.13
- ITRM N/A
- 52 Week Low
- OPTN $4.82
- ITRM $0.81
- 52 Week High
- OPTN $31.50
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- OPTN 44.78
- ITRM 46.16
- Support Level
- OPTN $5.20
- ITRM $1.42
- Resistance Level
- OPTN $6.49
- ITRM $1.58
- Average True Range (ATR)
- OPTN 0.50
- ITRM 0.11
- MACD
- OPTN 0.04
- ITRM 0.02
- Stochastic Oscillator
- OPTN 44.19
- ITRM 61.76
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.